Thermo Fisher Scientific reported second-quarter 2026 adjusted earnings of $6.03 per share, up 13% year over year and beating the Zacks Consensus Estimate by 5.6%. Revenues rose 10% to $11.99 billion, surpassing the consensus mark by 2.67%, supported by 5% organic revenue growth and strengthening customer activity across end markets. The company's four business segments all posted gains, with Life Sciences Solutions revenues increasing 12.6% to $2.82 billion, Laboratory Products and Biopharma Services climbing 11.6% to $6.69 billion, Analytical Instruments advancing 6.9% to $1.85 billion, and Specialty Diagnostics growing 6.3% to $1.21 billion. Adjusted operating income increased 15% to $2.74 billion, and the adjusted operating margin widened 90 basis points to 22.8%. Thermo Fisher also repurchased $1 billion of stock during the quarter and announced the divestiture of its microbiology business. Following the earnings announcement, TMO stock rose 4.4% in pre-market trading.
Thermo Fisher Scientific IncThermo Fisher reported Q2 earnings and revenues that beat estimates, with strong segment growth and margin expansion, and announced a $1B buyback.
Danaher Corporation
Elevance Health Inc
Intuitive Surgical Inc